JP6205363B2 - ハイブリッド定常領域 - Google Patents

ハイブリッド定常領域 Download PDF

Info

Publication number
JP6205363B2
JP6205363B2 JP2014532118A JP2014532118A JP6205363B2 JP 6205363 B2 JP6205363 B2 JP 6205363B2 JP 2014532118 A JP2014532118 A JP 2014532118A JP 2014532118 A JP2014532118 A JP 2014532118A JP 6205363 B2 JP6205363 B2 JP 6205363B2
Authority
JP
Japan
Prior art keywords
antibody
region
heavy chain
human
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014532118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501291A5 (OSRAM
JP2015501291A (ja
Inventor
ジェイ．， ユン ソウ，
ジェイ．， ユン ソウ，
ナオヤ ツルシタ，
ナオヤ ツルシタ，
Original Assignee
ジェイエヌ バイオサイエンシーズ エルエルシー
ジェイエヌ バイオサイエンシーズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェイエヌ バイオサイエンシーズ エルエルシー, ジェイエヌ バイオサイエンシーズ エルエルシー filed Critical ジェイエヌ バイオサイエンシーズ エルエルシー
Publication of JP2015501291A publication Critical patent/JP2015501291A/ja
Publication of JP2015501291A5 publication Critical patent/JP2015501291A5/ja
Application granted granted Critical
Publication of JP6205363B2 publication Critical patent/JP6205363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2014532118A 2011-09-26 2012-09-26 ハイブリッド定常領域 Active JP6205363B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539416P 2011-09-26 2011-09-26
US61/539,416 2011-09-26
PCT/US2012/057393 WO2013049254A1 (en) 2011-09-26 2012-09-26 Hybrid constant regions

Publications (3)

Publication Number Publication Date
JP2015501291A JP2015501291A (ja) 2015-01-15
JP2015501291A5 JP2015501291A5 (OSRAM) 2015-11-19
JP6205363B2 true JP6205363B2 (ja) 2017-09-27

Family

ID=47996377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014532118A Active JP6205363B2 (ja) 2011-09-26 2012-09-26 ハイブリッド定常領域

Country Status (6)

Country Link
US (2) US8952134B2 (OSRAM)
EP (1) EP2760891B1 (OSRAM)
JP (1) JP6205363B2 (OSRAM)
CN (1) CN103974977A (OSRAM)
CA (1) CA2849765C (OSRAM)
WO (1) WO2013049254A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
EP2760891B1 (en) 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
KR102089526B1 (ko) 2012-05-10 2020-03-17 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
IN2015DN01361A (OSRAM) 2012-08-02 2015-07-03 Jn Biosciences Llc
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AU2014332458B2 (en) * 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
MX2016010953A (es) * 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
WO2015167948A1 (en) 2014-04-30 2015-11-05 Albert Einstein College Of Medicine Of Yeshiva University Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102435324B1 (ko) * 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
WO2016154593A1 (en) * 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016164480A1 (en) * 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
GB201515745D0 (en) * 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins
SG10201911561SA (en) * 2016-01-27 2020-02-27 CSL Behring Lengnau AG Recombinant igg fc multimers
AU2017300647A1 (en) * 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
WO2018187702A2 (en) * 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
IL322042A (en) * 2017-05-08 2025-09-01 Adimab Llc Anti-CD3 binding sites and antibodies containing them, and methods of making and using them
KR20200123782A (ko) * 2018-02-26 2020-10-30 아이쥐엠 바이오사이언스 인코포레이티드 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도
AU2019286396A1 (en) 2018-06-14 2020-12-17 Bioatla, Inc. Multi-specific antibody constructs
EP3806903B1 (en) * 2018-06-14 2024-02-14 2seventy bio, Inc. Cd79a chimeric antigen receptors
JP2022505663A (ja) * 2018-10-23 2022-01-14 アイジーエム バイオサイエンシズ インコーポレイテッド ＩｇＭ－Ｆｃベース及びＩｇＡ－Ｆｃベースの多価結合分子
CN113271972B (zh) * 2018-11-14 2025-06-17 Jn生物科学有限责任公司 用于替代IVIG的多聚体杂交Fc蛋白
MA56212A (fr) * 2019-06-14 2022-04-20 2Seventy Bio Inc Compositions et méthodes de traitement du cancer
AU2021228098B2 (en) * 2020-02-27 2024-11-21 Huahui Health Ltd. Soluble ACE2 and fusion protein, and applications thereof
WO2022080912A1 (ko) * 2020-10-16 2022-04-21 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
CN116769042A (zh) * 2021-06-17 2023-09-19 东莞市朋志生物科技有限公司 嵌合的免疫球蛋白
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Engineered t cell receptors fused to binding domains from antibodies
KR20250008809A (ko) 2022-04-08 2025-01-15 리제너론 파마슈티칼스 인코포레이티드 다분할 수용체 및 신호전달 복합체
WO2024196707A2 (en) * 2023-03-17 2024-09-26 The Board Of Trustees Of The University Of Illinois Chimeric antibody molecules based on tetrameric teleost immunoglobulin m
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法
KR20250173023A (ko) * 2024-05-30 2025-12-10 주식회사 아이엠바이오로직스 J 사슬에 연결되는 링커 및 이를 포함하는 j 사슬 복합체
CN119638846B (zh) * 2025-01-09 2025-11-04 康复大学青岛中心医院 uMtCK抗体或其抗原结合片段

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719963D0 (en) * 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
AU2001257445B2 (en) 2000-04-28 2006-11-02 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
MXPA03006358A (es) * 2001-01-17 2004-12-02 Trubion Pharmaceuticals Inc Proteinas de fusion dominio de enlace-inmunoglobulina.
RU2003129528A (ru) * 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
EP1687486A1 (en) * 2003-11-13 2006-08-09 DSM IP Assets B.V. Use of a vulcanised thermoplastic elastomer or styrene-ethylene-butadiene-styrene polymer as infill material in artificial turf systems
EP2162471A1 (en) * 2007-06-08 2010-03-17 Université de la Méditerranée Compositions and methods for treating pancreatic tumors
EP2760891B1 (en) 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions

Also Published As

Publication number Publication date
WO2013049254A1 (en) 2013-04-04
CA2849765A1 (en) 2013-04-04
EP2760891B1 (en) 2018-11-07
US20130089547A1 (en) 2013-04-11
JP2015501291A (ja) 2015-01-15
US8952134B2 (en) 2015-02-10
EP2760891A1 (en) 2014-08-06
EP2760891A4 (en) 2015-06-24
CA2849765C (en) 2021-10-19
US20150073130A1 (en) 2015-03-12
CN103974977A (zh) 2014-08-06

Similar Documents

Publication Publication Date Title
JP6205363B2 (ja) ハイブリッド定常領域
US10053517B2 (en) Hybrid constant regions
US9540442B2 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
JP7062025B2 (ja) 修飾ｊ鎖
CN113301919B (zh) 激活免疫细胞的双特异性抗体
US20150038682A1 (en) Antibodies or fusion proteins multimerized via homomultimerizing peptide
US20230340114A1 (en) Novel anti-lilrb4 antibodies and derivative products
KR20200003845A (ko) 이중특이성 재조합단백질 및 이의 응용
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
JP2022518530A (ja) 新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体
JP2022504826A (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
TW202346368A (zh) 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
CN117157314A (zh) Pd-l1抗体、融合蛋白及其用途
TWI906278B (zh) 經遮蔽之il-12細胞激素及其裂解產物
JP2025540657A (ja) 抗ｃｄ３抗体
HK40046552A (en) Antibodies specific for cd3 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170904

R150 Certificate of patent or registration of utility model

Ref document number: 6205363

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250